Electroacupuncture may reduce hot flashes among breast cancer survivors
the ONA take:
Electroacupuncture may be more effective and safer than gabapentin for managing hot flashes among breast cancer survivors, according to a new study published online ahead of print in the Journal of Clinical Oncology.
For the study, researchers from the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, and colleagues sought to compare the effects of electroacupuncture with gabapentin for hot flashes among breast cancer survivors.
Researchers enrolled 120 breast cancer survivors who were experiencing bothersome hot flashes at least twice per day day. Participants were randomly assigned to receive 8 weeks of electroacupuncture or gabapentin once daily with placebo acupuncture or pills.
Results showed that by week 8, patients in the electroacupuncture group experienced the greatest reduction in hot flash composite score, followed by placebo electroacupuncture, gabapentin, and placebo pills (P≤0.001).
In regard to safety, patients in the gabapentin group experienced the greatest amount of treatment-related adverse events, followed by placebo pills, electroacupuncture, and placebo electroacupuncture (P=0.005).
By week 24, electroacupuncture was still the most effective treatment for reducing hot flash composite score. The authors note that these findings need to be confirmed in a larger randomized controlled trial with long-term follow-up.
Electroacupuncture may be more effective and safer than gabapentin for managing hot flashes among breast cancer survivors.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|